102 related articles for article (PubMed ID: 19995227)
21. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer.
Paramore LC; Thomas SK; Knopf KB; Cragin LS; Fraeman KH
Clin Colorectal Cancer; 2006 May; 6(1):52-8. PubMed ID: 16796792
[TBL] [Abstract][Full Text] [Related]
22. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
Eisenbeis CF; Grainger A; Fischer B; Baiocchi RA; Carrodeguas L; Roychowdhury S; Chen L; Banks AL; Davis T; Young D; Kelbick N; Stephens J; Byrd JC; Grever MR; Caligiuri MA; Porcu P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6101-10. PubMed ID: 15447996
[TBL] [Abstract][Full Text] [Related]
23. Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin's lymphoma: results from the University of Nebraska Medical Center 1989 to 1995.
Freeman M; Vose J; Bennett C; Anderson J; Kessinger A; Turner K; Pierson J; Bishop M; Bierman P; Armitage J
Bone Marrow Transplant; 1999 Sep; 24(6):679-84. PubMed ID: 10490736
[TBL] [Abstract][Full Text] [Related]
24. Primary non-Hodgkin's lymphoma of the breast: breast conservation therapy in two patients.
Lee KC; Chang HT; Chen CJ; Mok KT
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Sep; 62(9):633-8. PubMed ID: 10502855
[TBL] [Abstract][Full Text] [Related]
25. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma.
Doorduijn JK; Buijt I; van der Holt B; van Agthoven M; Sonneveld P; Uyl-de Groot CA
Haematologica; 2004 Sep; 89(9):1109-17. PubMed ID: 15377472
[TBL] [Abstract][Full Text] [Related]
26. [Immunotherapy of colorectal cancer--overview and perspectives].
Schimanski CC; Hörner V; Kanzler S; Galle PR; Moehler M
Z Gastroenterol; 2006 Aug; 44(8):673-81. PubMed ID: 16902899
[TBL] [Abstract][Full Text] [Related]
27. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment.
Edwards BK; Brown ML; Wingo PA; Howe HL; Ward E; Ries LA; Schrag D; Jamison PM; Jemal A; Wu XC; Friedman C; Harlan L; Warren J; Anderson RN; Pickle LW
J Natl Cancer Inst; 2005 Oct; 97(19):1407-27. PubMed ID: 16204691
[TBL] [Abstract][Full Text] [Related]
28. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma.
Al-Tourah AJ; Gill KK; Chhanabhai M; Hoskins PJ; Klasa RJ; Savage KJ; Sehn LH; Shenkier TN; Gascoyne RD; Connors JM
J Clin Oncol; 2008 Nov; 26(32):5165-9. PubMed ID: 18838711
[TBL] [Abstract][Full Text] [Related]
29. Age group specific gap between treatment cost of and mortality due to breast and colorectal cancer.
Boncz I; Sebestyén A; Pintér I; Betlehem J; Kriszbacher I; Csere T; Mangel L; Bódis J
J Clin Oncol; 2007 Oct; 25(28):4501-2; author reply 4502-3. PubMed ID: 17906215
[No Abstract] [Full Text] [Related]
30. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines.
Maloney DG
J Clin Oncol; 2005 Sep; 23(26):6421-8. PubMed ID: 16155029
[TBL] [Abstract][Full Text] [Related]
31. Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment.
Kutikova L; Bowman L; Chang S; Long SR; Arning M; Crown WH
Leuk Lymphoma; 2006 Aug; 47(8):1535-44. PubMed ID: 16966264
[TBL] [Abstract][Full Text] [Related]
32. Clinical update on oncology treatments and trends.
Brooks BJ
Am J Manag Care; 2006 Mar; 12(3 Suppl):S43-70; quiz S71-2. PubMed ID: 16551203
[TBL] [Abstract][Full Text] [Related]
33. Risk of non-Hodgkin's lymphoma and family history of lymphatic, hematologic, and other cancers.
Chatterjee N; Hartge P; Cerhan JR; Cozen W; Davis S; Ishibe N; Colt J; Goldin L; Severson RK
Cancer Epidemiol Biomarkers Prev; 2004 Sep; 13(9):1415-21. PubMed ID: 15342441
[TBL] [Abstract][Full Text] [Related]
34. Hospital health care resource utilization and costs of colorectal cancer during the first 3-year period following diagnosis in Switzerland.
Delcò F; Egger R; Bauerfeind P; Beglinger C
Aliment Pharmacol Ther; 2005 Mar; 21(5):615-22. PubMed ID: 15740546
[TBL] [Abstract][Full Text] [Related]
35. Costs differences among monoclonal antibodies-based first-line oncology cancer protocols for breast cancer, colorectal carcinoma and non-Hodgkin's lymphoma.
Jakovljevic M; Gutzwiller F; Schwenkglenks M; Milovanovic O; Rancic N; Varjacic M; Stojadinovic D; Dagovic A; Matter-Walstra K
J BUON; 2014; 19(4):1111-20. PubMed ID: 25536624
[TBL] [Abstract][Full Text] [Related]
36. Economic assessment in the management of non-Hodgkin's lymphoma.
van Agthoven M; Uyl-de Groot CA; Sonneveld P; Hagenbeek A
Expert Opin Pharmacother; 2004 Dec; 5(12):2529-48. PubMed ID: 15571470
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of soluble CD44 in patients with breast and colorectal carcinomas and non-Hodgkin's lymphoma.
Lockhart MS; Waldner C; Mongini C; Gravisaco MJ; Casanova S; Alvarez E; Hajos S
Oncol Rep; 1999; 6(5):1129-33. PubMed ID: 10425314
[TBL] [Abstract][Full Text] [Related]
38. Economic disparities in treatment costs among ambulatory Medicaid cancer patients.
Mullins CD; Snyder SE; Wang J; Cooke JL; Baquet C
J Natl Med Assoc; 2004 Dec; 96(12):1565-74. PubMed ID: 15622686
[TBL] [Abstract][Full Text] [Related]
39. Economic/societal burden of metastatic breast cancer: a US perspective.
Allen JM
Am J Manag Care; 2010 Sep; 16(9):697-704. PubMed ID: 20873957
[TBL] [Abstract][Full Text] [Related]
40. Using appropriate comparisons in economic evaluations. An exercise in Belgium.
Van Tiggelen O; Storme G; Torfs K; Van den Berge D
Int J Technol Assess Health Care; 1999; 15(1):243-53. PubMed ID: 10407610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
